[144] Voyager Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. (VYGR) filed a Form 144 notifying a proposed sale of 19,000 common shares that vested as restricted stock on 04/01/2025. The shares are held at Fidelity Brokerage Services and were acquired as compensation. The filer estimates an aggregate market value of $70,680 and reports 55,468,806 shares outstanding; the approximate sale date is 08/18/2025 on NASDAQ. The filer reports no sales in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.

Positive

• Full disclosure of material sale details including acquisition date, nature, broker, and intended sale date
• Transaction is immaterial in size relative to outstanding shares (19,000 shares vs. 55,468,806 outstanding), suggesting limited market impact

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider notice for vested compensation, representing a very small portion of outstanding shares.

The Form 144 documents a planned sale of 19,000 vested common shares acquired as restricted stock vesting on 04/01/2025. The filing lists Fidelity Brokerage Services as the broker and an approximate sale date of 08/18/2025 on NASDAQ. With 55,468,806 shares outstanding and an aggregate market value reported at $70,680, the position is immaterial relative to total outstanding stock, indicating limited direct market impact.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements and includes the standard attestation about material information.

The notice fulfills regulatory disclosure for proposed insider sales under Rule 144, specifying acquisition date, nature (restricted stock vesting), payment as compensation, and broker details. The filer also affirms absence of undisclosed material adverse information, which is the customary attestation. No additional governance or compliance concerns are apparent from the document alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	19000	70680.00	55468806	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/01/2025	Restricted Stock Vesting	Issuer			19000	04/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does Voyager Therapeutics (VYGR) propose to sell?

The filer proposes to sell 19,000 common shares that vested as restricted stock on 04/01/2025.

When and where is the proposed sale scheduled for VYGR shares?

The approximate sale date is 08/18/2025 and the filing lists NASDAQ as the exchange with Fidelity Brokerage Services as broker.

What is the reported aggregate market value and outstanding shares noted in the Form 144?

The aggregate market value is reported as $70,680 and the number of shares outstanding is 55,468,806.

How were the shares acquired according to the filing?

The shares were acquired through restricted stock vesting on 04/01/2025 and payment is listed as compensation.

Has the filer sold any VYGR securities in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.